The Humane Research Trust’s Post

Expert Reviews in Molecular Medicine are publishing a special edition of their journal, which is focusing on advances in non-animal models and data analysis for drug development. They're currently seeking review submissions on animal-free approaches such as 3D in vitro cell cultures and mathematical and computer modelling, and more. 🗓️ Submission deadline: 31st January 2025 🔗 Learn more and submit your paper: https://lnkd.in/eztcPKhT #NAMs #MedicalJournal #DrugDevelopment

It’s a multimodal world 🧬🧪. What does that mean for your scientific informatics tools? To accelerate the development of multimodal therapeutics, chemists and molecular biologists need a way to work together more effectively ⬇️ Download our latest whitepaper to find the best approach to multimodal entity registration that will support your development of advanced therapeutics 👩🏻🔬. Get it here: https://lnkd.in/eTmJVbiY

#FOGBoston is less than 2 weeks away! There’s going to be lots of coverage of methods for how to make the most out of clinico-genomics. Another talk at #FOGBoston covering this topic is from, Jadwiga Bienkowska, Senior Director, Head of Computational Biology R&D, Pfizer She will be presenting ‘Unravelling Mechanisms of Resistance to CDK4/6i With the Power of ML Approaches and RWE Clinico-Genomics Data’, which will show the discovery of resistance mechanisms evolution trajectories and translation of resistance mechanisms between preclinical models and patients’ data. There’s still time to register: https://hubs.la/Q02s_nFS0

#analyticalchemistry news In the rapidly evolving field of #chemistry, a significant advancement has been made in the area of #DNA analysis, which could have widespread implications across various scientific and medical disciplines. Recent research published in *Analyst* by a team of esteemed scientists unveils a novel method that leverages the Cas12a/crRNA system for the detection and analysis of cell-free DNA, cfDNA, through a colourimetric approach. This innovative method hinges on a process called "self-priming mediated chain extension," which enhances the sensitivity and accessibility of cfDNA analysis outside of traditional laboratory settings. This advancement offers a streamlined approach for detecting cfDNA, which is present in small quantities in bodily fluids, and can provide crucial insights into various physiological and pathological states, including cancer and other genetic conditions. The key feature of this research is its potential to simplify the cfDNA analysis process by facilitating its application in broader contexts, such as at points of care, without necessitating complex equipment or extensive laboratory expertise. By enabling a more straightforward and visual detection method through colourimetric change, it becomes possible to integrate this technique into routine clinical diagnostics and personal health monitoring. The practical benefits of this technology could be transformative. By allowing more accessible and rapid cfDNA analysis, it holds the promise of improving early diagnosis and monitoring of diseases, thereby leading to more timely and accurate treatment decisions. This advancement not only makes cutting-edge genetic analysis more accessible but also sets the stage for future innovations that can bring #biotechnology and medical diagnostics to broader parts of society. Explore this groundbreaking research further: [Link to article] #DNAanalysis #cfDNA #biotechnology #medicaldiagnostics #scientificinnovation #healthcare #ClinicalChemistry #sciencecommunication, If you want to know more about #analyticalchemistry news, follow me: https://lnkd.in/d29pbjb9

Super excited to be launching public data sets on commercially interesting treatments and human cell lines and making available to folks training AI models in biology. Our largest public data set just got posted -- 934 GB of RNA-seq data exploring dose-dependent drug responses of primary human cell lines You can learn more and download the data set here: https://lnkd.in/egYsU5A9 We can also make custom data sets for your cell line or perturbation of interest ! Just reach out !

Spatial omics will be a key part of how we arrive at the virtual 3D human models and the ‘Holy Grail’ of biology 🔮 We wrote this article to explain why we must move beyond the one-dimensional view of cell omics toward the era of spatial biology. 👉 Read it here: https://lnkd.in/dFY-J_NG Our team at ZS Discovery is on a mission to help clients translate spatial omics to progress in drug discovery. “Progress in science depends on new techniques, new discoveries and new ideas - probably in that order”, as Nobel laureate Sydney Brenner famously described scientific transformations. I wonder what the AlphaFold-like moment will look like for spatial omics? Thanks to colleagues Francisco, Christina, Scott and Thomas for sharing their insights and co-authoring the article. #SpatialOmics #DrugDiscovery #Pharma

Summertime is reflection time ☀️💭 Over the past eight years I have been working in the field of gene expression analysis, actively engaging in the evolution from microarrays through RNA-seq to single-cell RNA-seq 🧬 Now, it is time for spatial transcriptomics, which has the potential to revolutionize our understanding of tissue complexity and cell-cell interactions 🤝 Technological leaps like these bring unique analytical challenges: Tackling these to dig out biological answers was my driver for going into bioinformatics - and what a great choice that was 👩💻 #SpatialOmics #DrugDiscovery

Today we highlight a recent work from the groups of Mathew H. Horrocks and Lynne Ragen from the The University of Edinburgh and the group of Sonia Gandhi from The Francis Crick Institute in London. The article titled Super-Resolution Imaging of Proteins Inside Live Mammalian Cells with mLIVE-PAINT, describes an innovative approach for #SuperResolution #imaging of live cells. The traditional #DNAPAINT approach relies on fixed cells, where proteins of interest are labeled with specific #antibodies that are fused to a single #DNA strand. Researchers then supplement the cells with a fluorescently-labeled complementary DNA strand. The annealing of both strands leads to a well-defined signal that can be recorded and analyzed. While this approach is a very useful #SMLM technique, it is not compatible with live cell imaging, as it requires both labeling with antibodies and the introduction of fluorescent DNA strands. Here, the scientists sought an alternative labeling method that is compatible with live cells: Instead of using antibodies, they engineered two sets of fusion proteins: The first, a fusion of their proteins of interest with a specific peptide; the second, a fusion of a fluorescent protein and another peptide, that partners with the first one. The fusion proteins are well tolerated by cells and they do not require any external labeling reagents, making them excellent candidates for #LiveCellImaging. The binding of the peptides concentrates the fluorescent protein around the protein of interest, allowing the scientist to record the precise cellular localizations with the #Nanoimager. Read the paper: https://lnkd.in/eK5rdAJG

Some exciting advancements in precision medicine over the past week: 💫 The injunction halting NanoString Technologies, Inc. CosMx Spatial Molecular Imager in Germany has been lifted, bringing good news for Bruker. 🙏 Thermo Fisher Scientific has successfully acquired Olink Proteomics.  📰 BePRECISE was founded to improve research reporting in precision medicine, thereby enabling the best possible outcomes for all. Produced by a Consortium of 23 global experts in precision medicine, cardiometabolic diseases, statistics, editorial, and lived experience, plus researchers in low, middle, and high-income countries, this guideline will improve the accuracy, safety, and health equity in precision medicine. 🍃 Metabolon, Inc. has expanded its library to include 70 pesticides. 🤝 Inocras Inc. and Watchmaker Genomics are teaming up to enhance genomic research and clinical applications. 💉 Genomics plc and Vertex Pharmaceuticals have extended their partnership, leveraging human genetics and ML to enhance the discovery and development of new precision medicines. #PrecisionMedicine #Advancements #Research #Partnerships #Genomics #ML #Healthcare

What happens when two scientists both came up with (or say they came up with) the same invention? The Fed. Circuit earlier this week heard argument in a PTO "interference" appeal, with hundreds of millions if not billions of dollars at stake over who ultimately gets the patent for a CRISPR-Cas9 gene editing system that works in animal/human cells. Interferences are an odd sub-specialty within the already highly specialized patent bar. They've always been rare and are headed toward extinction as the U.S. has shifted to a first-to-file system for awarding patents. But in 2012, when the foundational work on CRISPR was happening, we were in a first-to-invent system where a scientist could get a priority date ahead of her patent application in the event she conceived of an invention and diligently worked to reduce it to practice. Anyway, more than 50 people attended an oral argument, where Judges Hughes and Reyna both seemed skeptical of a PTAB interference decision, in which that tribunal rejected arguments from Nobel Prize-winning scientists in France and at the Univ. of California that they were entitled to a priority date tied to announcements they'd gotten CRISPR-Cas9 working in a generic environment. The Broad (pronounced Broh'd) Institute beat the California group to the punch when it comes to modifying more complex animal cells. A good deal of the questioning focused on whether the work at Broad was itself inventive in nature or just routine experimentation. https://lnkd.in/ekaajY5D